138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Catherine Thiéblemont(Assistance Publique – Hôpitaux de Paris), Nathan Fowler(The University of Texas MD Anderson Cancer Center), Peter A. Riedell(University of Chicago), Jason Butler(Oslo University Hospital), P. Joy Ho(The University of Sydney), Rafael Jacques Ramos(Novartis (United States)), Ram Malladi(Cambridge University Hospitals NHS Foundation Trust), Koji Kato(AbbVie (United States)), M. J. Kersten(Amsterdam University Medical Centers), Takanori Teshima(Hokkaido University), Monalisa Ghosh(Michigan Medicine), A. Chen(Oregon Health & Science University), Piers Patten, Joseph P. McGuirk(University of Kansas Medical Center), Emmanuel Bachy(Université Claude Bernard Lyon 1), Andreas Viardot(University Hospital Ulm), Aiesha Zia(Novartis (Switzerland)), L. Nastoupil(The University of Texas MD Anderson Cancer Center), M. Dreyling(LMU Klinikum), Stephen J. Schuster(UPMC Hillman Cancer Center), Hideo Harigae(Tohoku University), Julio C. Chávez(Moffitt Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Arne Kolstad(Oslo University Hospital), C. Andreadis(University of California, San Francisco), Pier Luigi Zinzani(University of Bologna), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Michael Dickinson(The Royal Melbourne Hospital), Domenico Germano, R. Awasthi(Novartis (United States)), Fritz Offner, Peihong Hsu(Novartis (Switzerland)), B. vonTresckow(University of Cologne), Leslie Popplewell(City Of Hope National Medical Center)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859